Cargando…
In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS/HIPEC. The aim of this study was to determi...
Autores principales: | Said, Ibrahim, Ubink, Inge, Ewalds, Roos S. G., Arkesteijn, Johanna G. T., Verheul, Henk M. W., de Wilt, Johannes H. W., Dekker, Helena M., Bremers, Andreas J. A., de Reuver, Philip R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246798/ https://www.ncbi.nlm.nih.gov/pubmed/35430666 http://dx.doi.org/10.1245/s10434-022-11718-7 |
Ejemplares similares
-
Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC
por: Graf, Wilhelm, et al.
Publicado: (2019) -
Reply to: “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation”
por: Horvath, Philipp, et al.
Publicado: (2021) -
Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma
por: Dietz, Michelle V., et al.
Publicado: (2022) -
Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: Patient-Reported Outcomes of a Randomized Phase II Trial
por: Bakkers, C., et al.
Publicado: (2023) -
2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer
por: Hübner, Martin, et al.
Publicado: (2023)